Research Article
Risk Factors for Symptomatic Pericardial Effusions Posthematopoietic Stem Cell Transplant
Table 1
Characteristics of patients developing pericardial effusions.
| Factors | N | % |
| Overall | 15 | 100 | Sex | Male | 10 | 66.7 | Female | 5 | 33.3 | Diagnosis | Malignancy | 5 | 33.3 | Hemoglobinopathy | 6 | 40 | Immunodeficiency | 4 | 26.7 | Conditioning regimen | Myeloablative | 13 | 86.7 | With cyclophosphamide | 13 | 86.7 | Reduced intensity | 2 | 13.3 | Hx CMV reactivation | Yes | 7 | 46.7 | No | 8 | 53.5 | Active infection within 2 weeks of PEF diagnosis | Yes | 13 | 86.7 | No | 2 | 13.3 | GVHD active at PEF dx | Yes | 4 | 26.7 | No | 11 | 73.3 | PEF diagnosis and time from BMT | Under day +100 | 12 | 80.0 | Over day +100 | 3 | 20.0 | Patients on immunosuppression at time of PEF diagnosis | Yes | 14 | 93% | No | 1 | 7% |
|
|
CMV, cytomegalovirus; PEF, pericardial effusion; GVHD, graft versus host disease.
|